Welcome to the Desert Angels™. We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies. The organization serves as a forum for its over 90 members, who invest individually from their personal funds. Since 2000, Desert Angel members have invested over $37 million in more than 85 presenting companies.

Tucson drug startup drops initial public stock offering

by Curtis Gunn on November 16th, 2016 at 3:27pm

A Tucson-based company developing cancer-prevention drugs has withdrawn its initial public offering of stock.

But Cancer Prevention Pharmaceuticals will keep moving forward with trials of its cancer-prevention drugs with the backing of its pharma industry partners, the company’s CEO said.

Read full article here

Comment

Filed under: Funded Companies, Press

Tech effect: Arizona’s thriving software and optics industries

by Curtis Gunn on November 9th, 2016 at 3:31pm

If you grew up in Arizona, the Five C’s of Arizona — copper, cattle, cotton, citrus and climate — have been drilled into your head as the first mainstays of Arizona’s economy since elementary school.

Arizona’s economic base has morphed over the years, transitioning into a more knowledge-based economy. In the 1990s, after an economic analysis of the state’s main industries Arizona found itself as home to two technology-based high-wage industries: software development and optics and photonics.

Read full article here

Comment

Filed under: Press

Tucson’s NuvOx wins $300K grant

by Curtis Gunn on November 1st, 2016 at 4:31pm

Tucson-based biotech drug startup NuvOx Pharma has been awarded a grant of nearly $300,000 from the National Cancer Institute to study a targeted contrast agent for breast cancer.

Dr. Evan Unger, a University of Arizona radiology professor and co-founder of NuvOx, is co-principal investigator of the grant along with Dr. Juergen Willmann, professor of radiology and a clinical division chief in the radiology department at Stanford University Medical Center.

Read full article here

Comment

Filed under: Uncategorized

Dow Jones: Arizona venture capital plummets to under $20M

by Curtis Gunn on October 20th, 2016 at 8:29pm

Arizona companies did not capitalize much in the third quarter, according to data from Dow Jones VentureSource.

Companies seeking venture capital brought home checks totaling less than $17 million, compared to $55 million in the second quarter this year and $177 million in Q1 2016.

Read full article here

Comment

Filed under: Funded Companies, Press

New partnership, NIH grant push research forward

by Curtis Gunn on October 3rd, 2016 at 11:28pm

Shelby Kutty, M.D., Ph.D. was recently informed that the project, “Fibrin Targeted Microbubbles and Ultrasound for Treatment of Endocarditis,” has been funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Kutty is co-principal investigator with Evan Unger, M.D., co-founder of NuvOx Pharma. Dr. Unger also is professor of radiology at University of Arizona Health Sciences.

NuvOx will develop microbubbles specifically designed to target fibrin. UNMC will use ultrasound to break the bubbles, and with them, the vegetation, while co-administering an antibiotic and also using ultrasound for live imaging purposes.

Read full article here

Comment

Filed under: Funded Companies, Press

SalutarisMD Honored with AZBio Fast Lane Award As It Ramps Up for Commercialization of Sight-saving Treatment

by Curtis Gunn on September 19th, 2016 at 5:28pm

As it prepares for its commercial product launch in Europe and new clinical studies in the United States, SalutarisMD® (Salutaris Medical Devices, Inc. and Salutaris Medical Devices, Ltd.) will be in the spotlight at the 2016 AZBio Awards on September 21, 2016 as they are honored with the AZBio Fast Lane Award.

The following day, on September 22, 2016, Dr. Laurence Marsteller, SalutarisMD® CEO will provide further updates to investors from across the United States at the White Hat Life Science Investor Conference.

Read full article here

Comment

Filed under: Uncategorized

Tempronics Successfully Closes $9.5M Series C Round

by Curtis Gunn on September 13th, 2016 at 4:36pm

Lear Corporation Leads Round and Enters into a Strategic Partnership to Bring a New Generation of Heating and Cooling Technology to the Automotive Market

Tempronics, a thermoelectric company with proprietary new technology in solid state heating and cooling, is partnering with the Lear Corporation (NYSE: LEA), a leading global supplier of automotive seating and electrical systems, to provide a new generation of thermal comfort to the automotive seating market. Other investors include Nth Power, the Desert Angels, management and individual investors.

Read full article here

Comment

Lear Enters into a Strategic Partnership with Tempronics and Secures Exclusive Rights to Thermoelectric Seat Heating and Cooling Technology for use in Automotive Applications

by Curtis Gunn on September 8th, 2016 at 4:26pm

Lear Corporation (NYSE: LEA), a leading global supplier of automotive seating and electrical systems, today announced that it has entered into a strategic partnership with Tempronics, pursuant to which Lear obtained a minority equity interest in Tempronics and also secured exclusive rights to its thermoelectric seat heating and cooling technology for automotive applications.

“This partnership will provide Lear with the ability to heat and cool seats faster utilizing less energy than any other system available today,” said Ray Scott, Lear’s executive vice president and president of Seating.

Read full article here

Comment

Beacon Biomedical Inc. Honored with AZBio Fast Lane Award as It Ramps up for Commercialization

by Curtis Gunn on September 8th, 2016 at 4:12pm

Beacon Biomedical’s progress towards its commercial product launch this fall will be in the spotlight at the 2016 AZBio Awards on September 21, 2016 as they are honored with the AZBio Fast Lane Award.

If early detection saves lives, then why, with all the billions of dollars being spent on patient education and awareness as to the life-saving benefits of routine cancer screening, are we seeing hundreds of thousands of people still dying each year from cancer? That question was the genesis behind Beacon Biomedical.

Read full article here

Comment

Filed under: News Releases, Press

FDA Allows NuvOx Pharma’s IND to Initiate Phase Ib Clinical Trial in Stroke.

by Curtis Gunn on August 19th, 2016 at 5:06pm

Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients.

The trial will be performed at the University of Arkansas Medical System in Little Rock, Arkansas under the direction of Dr. William Culp, Jonathan Fitch Distinguished Chair in Stroke. Dr. Culp said, “We have studied NVX-208 in a number of pre-clinical stroke models and found that administration of NVX-208 decreases the brain damage from stroke by over 80%. The only approved drug to treat stroke is t-PA, which has a risk of bleeding and is approved for use only up to 3 hours following stroke. Administration of NVX-208 prior to t-PA extended the time window of efficacy to at least 9-hours. NVX-208 has great potential to allow many more stroke patients to be treated and to improve their outcomes. This trial will determine the recommended dose of NVX-208 in stroke patients so that it can be subsequently tested in a randomized study in stroke patients.”

Read full article here

Comment

Filed under: Funded Companies, Press